All News
“Preventing” Arthritis in Psoriasis
The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.
Read Article
Cannabis Hospitalizations and Mortality Risk
A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death.
https://t.co/MQtR3etpEH https://t.co/ZB4byi81on
Dr. John Cush RheumNow ( View Tweet)
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/5igpgtdE1U https://t.co/5KOXRThzlk
Dr. John Cush RheumNow ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Cather treatment options in HS. The last 2 obviously in rheumatology's wheelhouse @RheumNow #RNL2025 https://t.co/vGfvQH05lv
Richard Conway RichardPAConway ( View Tweet)
New for HS
- Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2
- Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE)
Clinical trials:
IL23 failed, ILalpha failed
Brodulamab (IL17a) clinically meaningful response
TNF trials
@RheumNow #ACR2025 https://t.co/BfzwNQ1wUB
Links:
Eric Dein ericdeinmd ( View Tweet)
The ‘dark’ side of
#Hidradenitis #suppurativa
👇
Smell of leaking lesions #HS
⬆️skin folds, buttock, axilla, also thighs, neck
⬆️depression
@RheumNow #RNL2025
‘ If pt doesn’t get in gown then not ready for systemic #Rx!’
Jennifer Clay
#ClinicalPearl https://t.co/tZzz5tielt
Links:
Janet Pope Janetbirdope ( View Tweet)
-HS ttx👇
1. Lifestyle changes: smoking cessation, obesity.
2. Management of comorbidities.
3. 🔍HS- related autoimmune disorders.
4. FDA approved biologics:
-Adalimumab (PIONEER 1&2)
-Secukinumab (SUNRISE, SUNSHINE)
-Bimekizumab (BE HEARD 1&2)
"Theres no such… https://t.co/G5Voxrm3Kt https://t.co/dLGtoFZMd1
Links:
Adela Castro AdelaCastro222 ( View Tweet)
1/3 of #axial #PsA
👇
No #SI joint changes , only #axial
@RheumNow #RNL2025
Catherine Blackwell
#ClinicalPearl https://t.co/YmoipL1bME
Janet Pope Janetbirdope ( View Tweet)
Pregnancy is 🔥 inflammatory
Hard to interpret MRI of SI joints in setting of pregnancy
Ideally, don't score MRI during pregnancy or 1 year afterwards, would be affected by the pregnancy
If needed for clinical eval, focus on structural lesions like erosions
#RNL2025 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
Full read review and overview of Fibromyalgia - manifestations, pathophysiology, treatments and guidelines. Multidisciplinary, patient-centered treatment should includes a combination of pharmacological and nonpharmacological options. https://t.co/x4OVeQ5RJz https://t.co/i1fD6XQbnx
Dr. John Cush RheumNow ( View Tweet)
P2 Trial: DEU in PsA
Encouraging results for DCV 6 and 12 mg qd.
ACR20 63% for DCV 12 mg (p=0.0004)
Not yet FDA approved for PsA, only PsO
Pending P3
P2: DEU in SLE - PAISLEY
Improved SRI(4), CLASI-50 at w32
Merola
#RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Links:
Eric Dein ericdeinmd ( View Tweet)
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway RichardPAConway ( View Tweet)
MDA5 + Pts with #ILD in #dermatomyositis can improve!
@RheumNow @ACRheum #RNL2025
Data from Christina Charles-Schoeman
#ClinicalPearl
Her pearls
👇
#DM is a #vascular #disease
#CK is not reliable in chronic DM
Neg Abs don’t r/o #myositis https://t.co/hxomz70aq5
Janet Pope Janetbirdope ( View Tweet)
#RNL2025 @RheumNow
Dermatomyositis is VASCULAR disease
-IVIG may help DM by blocking complement deposition on endomysial capillaries
-CK levels not reliable
Pruritus common in up to 86% of DM patients
Dr. Charles-Schoeman, UCLA
Eric Dein ericdeinmd ( View Tweet)
#RNL2025 @RheumNow
JAKi in DM:
@JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response
145 case reports for tofa, bari, ruxolitinib.
Role in helping calcinosis? Pruritu?
Brepocitinib (JAK1/TYK2i) study
Eric Dein ericdeinmd ( View Tweet)
Pearls on Dermatomyositis:
-Negative myomarker does not r/o DM
-Pruritus can be a skin manifestation in DM🚨
-Combination therapy upfront =achieve faster remission
-Evidence for JAK inhibitors in management
-JAKis seem to have good effect in DM-calcinosis
-In DM with rapidly… https://t.co/J3iiDa6ph7 https://t.co/0WTHKa97bt
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Importance of not over-relying on lab tests. We can test for what we can test for, but this is not comprehensive. For me in clinical practice - Postive antibodies can confirm diagnosis of DM but negative cannot exclude it. @RheumNow #RNL2025 https://t.co/Kyfzne4BSD
Richard Conway RichardPAConway ( View Tweet)
Do you want to know a secret? @drcharitydean shares that doctors are wired in the same way that #AI is built. We understand the layers of complexity & are best equipped to partner with AI. @rheumnow #RNL2025
TheDaoIndex KDAO2011 ( View Tweet)
"Treat for the most likely, mitigate for the catastrophic" @drcharitydean (my hero!). Read her story in "Premonition" by Michael Lewis. She served an impt role in the COVID19 pandemic as a public health officer for CA. Her lecture is on re-inventing yourself.
@rheumnow #RNL2025 https://t.co/3ZWgClzez1
TheDaoIndex KDAO2011 ( View Tweet)